Boston Scientific Corp
BSX96.770USD
+6.140+6.77%
Handelsschluss 04/09, 16:00（ET）Kurse um 15 Minuten verzögert
142.69BMarktkapitalisierung
77.01KGV TTM
mehr Informationen über Boston Scientific Corp Unternehmen
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. It also owns the transcarotid artery revascularization (TCAR) platform.
Unternehmensinformationen
Unternehmens-codeBSX
Name des UnternehmensBoston Scientific Corp
IPO-datumMay 19, 1992
Gegründet am1979
CEOMr. Michael F. (Mike) Mahoney
Anzahl der mitarbeiter53000
WertpapierartOrdinary Share
GeschäftsjahresendeMay 19
Addresse300 Boston Scientific Way
StadtMARLBOROUGH
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl01752-1234
Telefon15086834000
Websitehttps://www.bostonscientific.com/en-US/Home.html
Unternehmens-codeBSX
IPO-datumMay 19, 1992
Gegründet am1979
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.87M
-3.05%
Mr. Charles J. Dockendorff, CPA
Mr. Charles J. Dockendorff, CPA
Independent Director
Independent Director
62.90K
--
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
52.64K
--
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
41.02K
-10.53%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
34.94K
--
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
3.55K
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
2.90K
--
Ms. Miriam O' Sullivan
Ms. Miriam O' Sullivan
Chief Human Resource Officer, Senior Vice President
Chief Human Resource Officer, Senior Vice President
--
--
Mr. Edward J. Ludwig
Mr. Edward J. Ludwig
Lead Independent Director
Lead Independent Director
--
--
Mr. Scott Olson
Mr. Scott Olson
Senior Vice President, President - Cardiac Rhythm Management and Diagnostics
Senior Vice President, President - Cardiac Rhythm Management and Diagnostics
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.87M
-3.05%
Mr. Charles J. Dockendorff, CPA
Mr. Charles J. Dockendorff, CPA
Independent Director
Independent Director
62.90K
--
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
52.64K
--
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
41.02K
-10.53%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
34.94K
--
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
3.55K
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Endoscopy
2.69B
16.04%
Interventional Cardiology Therapies
2.65B
15.79%
Peripheral Interventions
2.41B
14.39%
Cardiac Rhythm Management
2.28B
13.61%
Urology
2.20B
13.14%
Other
4.53B
27.03%
Nach RegionUSD
Name
Umsatz
Anteil
United States
10.21B
60.97%
EMEA (Europe, Middle East and Africa)
3.23B
19.28%
Asia Pacific
2.69B
16.04%
Latin America and Canada
624.00M
3.73%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Endoscopy
2.69B
16.04%
Interventional Cardiology Therapies
2.65B
15.79%
Peripheral Interventions
2.41B
14.39%
Cardiac Rhythm Management
2.28B
13.61%
Urology
2.20B
13.14%
Other
4.53B
27.03%
Aktionäre
Update-Zeit: Fri, Feb 21
Update-Zeit: Fri, Feb 21
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
8.94%
Fidelity Management & Research Company LLC
8.19%
BlackRock Institutional Trust Company, N.A.
5.19%
State Street Global Advisors (US)
4.32%
PRIMECAP Management Company
2.50%
Other
70.86%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
8.94%
Fidelity Management & Research Company LLC
8.19%
BlackRock Institutional Trust Company, N.A.
5.19%
State Street Global Advisors (US)
4.32%
PRIMECAP Management Company
2.50%
Other
70.86%
Art
Aktionäre
Anteil
Investment Advisor
43.30%
Investment Advisor/Hedge Fund
37.30%
Hedge Fund
3.29%
Pension Fund
2.97%
Research Firm
2.45%
Bank and Trust
1.64%
Sovereign Wealth Fund
1.47%
Private Equity
0.21%
Insurance Company
0.21%
Other
7.16%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
2544
1.38B
93.50%
+4.28M
2024Q4
2559
1.38B
93.61%
+1.09M
2024Q3
2417
1.37B
92.76%
-24.32M
2024Q2
2341
1.37B
93.29%
-18.17M
2024Q1
2227
1.37B
93.23%
-40.14M
2023Q4
2171
1.39B
94.95%
-25.34M
2023Q3
2110
1.39B
95.17%
-6.29M
2023Q2
2081
1.38B
95.67%
-15.63M
2023Q1
2012
1.36B
94.85%
-23.81M
2022Q4
1993
1.36B
94.66%
-54.91M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
132.25M
8.94%
+1.62M
+1.24%
Dec 31, 2024
Fidelity Management & Research Company LLC
121.20M
8.19%
-2.05M
-1.66%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
76.72M
5.19%
+7.50M
+10.84%
Dec 31, 2024
State Street Global Advisors (US)
63.96M
4.32%
+1.12M
+1.78%
Dec 31, 2024
PRIMECAP Management Company
36.93M
2.5%
-896.83K
-2.37%
Dec 31, 2024
Wellington Management Company, LLP
36.17M
2.45%
+3.34M
+10.19%
Dec 31, 2024
Geode Capital Management, L.L.C.
30.63M
2.07%
+1.04M
+3.52%
Dec 31, 2024
Capital World Investors
27.90M
1.89%
+6.22M
+28.67%
Dec 31, 2024
The Bollard Group, LLC
20.73M
1.4%
-510.32K
-2.40%
Dec 31, 2024
BlackRock Investment Management (UK) Ltd.
20.37M
1.38%
+757.90K
+3.86%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
iShares U.S. Medical Devices ETF
10.77%
Goldman Sachs Future Health Care Equity ETF
8.56%
iShares Health Innovation Active ETF
5.12%
NYLI Healthy Hearts ETF
4.83%
JPMorgan Healthcare Leaders ETF
4.25%
Global X Aging Population ETF
3.98%
Hennessy Stance ESG ETF
3.4%
FT Raymond James Multicap Growth Equity ETF
2.84%
Tema Cardiovascular and Metabolic ETF
2.83%
iShares US Thematic Rotation Active ETF
2.82%
Mehr Anzeigen
iShares U.S. Medical Devices ETF
Anteil10.77%
Goldman Sachs Future Health Care Equity ETF
Anteil8.56%
iShares Health Innovation Active ETF
Anteil5.12%
NYLI Healthy Hearts ETF
Anteil4.83%
JPMorgan Healthcare Leaders ETF
Anteil4.25%
Global X Aging Population ETF
Anteil3.98%
Hennessy Stance ESG ETF
Anteil3.4%
FT Raymond James Multicap Growth Equity ETF
Anteil2.84%
Tema Cardiovascular and Metabolic ETF
Anteil2.83%
iShares US Thematic Rotation Active ETF
Anteil2.82%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten